Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies

In this follow-up report, the relationship between total anti–Ebola virus (EBOV) and EBOV neutralizing-antibody concentrations, in convalescent plasma used in the treatment of Ebola disease, was evaluated to determine the effect on efficacy. To the Editor: We previously reported the results of a nonrandomized, controlled trial that compared survival among patients with Ebola virus (EBOV) disease who were treated with convalescent plasma with survival among historical controls. Although no safety concerns were identified, efficacy was not shown. 1 Notably, the levels of total anti-EBOV IgG and neutralizing antibodies in the infused plasma were unknown at the time of administration. 1 , 2 We now report on the association between the amount of total anti-EBOV IgG and neutralizing antibodies received and patient survival and on the changes in the amount of EBOV in their blood 24 hours . . .